Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues.

[1]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Clay B Marsh,et al.  MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. , 2009, Biochemical and biophysical research communications.

[3]  Doron Betel,et al.  Corrigendum: Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs , 2009 .

[4]  Martin L. Miller,et al.  Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs , 2009, Nature Biotechnology.

[5]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[6]  R. Haba,et al.  The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers , 2008, British Journal of Cancer.

[7]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[8]  M. Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[9]  Michael Kertesz,et al.  The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.

[10]  Teruhiko Yoshida,et al.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences , 2007, Journal of Human Genetics.

[11]  Chaoqian Xu,et al.  The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes , 2007, Journal of Cell Science.

[12]  Thomas D. Schmittgen,et al.  The Human Angiotensin II Type 1 Receptor +1166 A/C Polymorphism Attenuates MicroRNA-155 Binding* , 2007, Journal of Biological Chemistry.

[13]  D. Banerjee,et al.  A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance , 2007, Proceedings of the National Academy of Sciences.

[14]  B. White,et al.  The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-α (ERα) and Represses ERα Messenger RNA and Protein Expression in Breast Cancer Cell Lines , 2007 .

[15]  S. Takagi,et al.  MicroRNA regulates the expression of human cytochrome P450 1B1. , 2006, Cancer research.

[16]  M. Fukushima,et al.  Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT , 2006, British Journal of Cancer.

[17]  M. Fukushima,et al.  Tailor-made chemotherapy for non-small cell lung cancer patients. , 2006, Future oncology.

[18]  R. Diasio,et al.  Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals , 2005, Clinical Cancer Research.

[19]  M. Fukushima,et al.  Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. , 2005, Lung cancer.

[20]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[21]  U. Mau-Holzmann,et al.  Multiple Organ Failure due to 5-Fluorouracil Chemotherapy in a Patient with a Rare Dihydropyrimidine Dehydrogenase Gene Variant , 2004, Oncology Research and Treatment.

[22]  M. Oshimura,et al.  Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. , 2004, Human molecular genetics.

[23]  M. Fukushima,et al.  Aberrant Methylation of DPYD Promoter, DPYD Expression, and Cellular Sensitivity to 5-Fluorouracil in Cancer Cells , 2004, Clinical Cancer Research.

[24]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[25]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[26]  M. Franzblau.  Conflict of interest statement. , 2003, Journal of the American Academy of Dermatology.

[27]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[28]  T. Koga,et al.  Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues , 2002, International Journal of Clinical Oncology.

[29]  R. Diasio,et al.  Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. , 2002, Pharmacogenomics.

[30]  A. Fujioka,et al.  Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. , 2002, European journal of cancer.

[31]  A. V. van Kuilenburg,et al.  Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  M. Fukushima,et al.  Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. , 2001, International journal of oncology.

[33]  P. Vreken,et al.  Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Y. Sugiyama,et al.  Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[35]  M. Fukushima,et al.  Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  S. J. Johnston,et al.  Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  S. J. Johnston,et al.  Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Sludden,et al.  Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. , 1998, British Journal of Cancer.

[39]  P. Vreken,et al.  A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency , 1996, Journal of Inherited Metabolic Disease.

[40]  H. McLeod,et al.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. , 1996, The Journal of clinical investigation.

[41]  O. Dassonville,et al.  Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Spector,et al.  5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. , 1993, Biochemical pharmacology.

[43]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[44]  井上 健太郎.  Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer : in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase , 2005 .

[45]  S. Guichard,et al.  Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans , 2000, Cancer Chemotherapy and Pharmacology.

[46]  G. Peters,et al.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. , 1986, Cancer research.